NVOC
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B · BCBA:NVOC
5.54 USD−0.0600 −1.07%
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B (BCBA:NVOC) last traded at 5.54 USD, down 1.07% on the day. Over the past year the stock is down 13.03%. Its 52-week range is 5.33 to 6.70. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open5.54
Day range5.54 – 5.54
52-week range5.33 – 6.70
Volume1
Average volume (10 days)330
Market cap175.99 B
P/E1.39
EPS (TTM)3.99
Dividend yield4.40%
Beta (1 year)0.5319
Revenue (TTM)50.21 B
Employees68.79 K
Performance
−1.60%1 week
−0.89%1 month
−13.03%3 months
−13.03%6 months
−13.03%Year to date
−13.03%1 year
Technical rating
Neutral
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Latest headlines
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
- Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
- Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
- LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026
- Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
- Eli Lilly Wins Early Round in Novo Nordisk Ad FightGuruFocus · 27 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.